RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Guizhou Bailing Group Pharmaceutical Co Stock

Guizhou Bailing Group Pharmaceutical Co Revenue 2024

Guizhou Bailing Group Pharmaceutical Co Revenue

4.26 B CNY

Ticker

002424.SZ

ISIN

CNE100000PY3

In 2024, Guizhou Bailing Group Pharmaceutical Co's sales reached 4.26 B CNY, a 20.42% difference from the 3.54 B CNY sales recorded in the previous year.

The Guizhou Bailing Group Pharmaceutical Co Revenue history

YEARREVENUE (undefined CNY)GROSS MARGIN (%)
20234.2654,19
20223.5459,39
20213.1159,13
20203.0956,13
20192.8559,83
20183.1459,75
20172.5963,20
20162.2164,11
20151.960,68
20141.5760,79
20131.4160,10
20121.3753,60
20111.1454,32
20100.8651,47
20090.7344,85
20080.6145,72
20070.4547,65

Guizhou Bailing Group Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Guizhou Bailing Group Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Guizhou Bailing Group Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Guizhou Bailing Group Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Guizhou Bailing Group Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Guizhou Bailing Group Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Guizhou Bailing Group Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Guizhou Bailing Group Pharmaceutical Co’s growth potential.

Guizhou Bailing Group Pharmaceutical Co Revenue, EBIT and net profit per share

DateGuizhou Bailing Group Pharmaceutical Co RevenueGuizhou Bailing Group Pharmaceutical Co EBITGuizhou Bailing Group Pharmaceutical Co Net Income
20234.26 B undefined-396.21 M undefined-414.51 M undefined
20223.54 B undefined216.63 M undefined138.2 M undefined
20213.11 B undefined229.14 M undefined118.48 M undefined
20203.09 B undefined224.7 M undefined152.4 M undefined
20192.85 B undefined457.5 M undefined282.7 M undefined
20183.14 B undefined662.5 M undefined563.2 M undefined
20172.59 B undefined625.9 M undefined526.1 M undefined
20162.21 B undefined583.4 M undefined482.3 M undefined
20151.9 B undefined492.6 M undefined411.4 M undefined
20141.57 B undefined397.8 M undefined310.5 M undefined
20131.41 B undefined356.3 M undefined269.6 M undefined
20121.37 B undefined280.4 M undefined221.8 M undefined
20111.14 B undefined279.2 M undefined208.4 M undefined
2010863.8 M undefined198.9 M undefined158.2 M undefined
2009734.5 M undefined143.6 M undefined111.7 M undefined
2008607.4 M undefined114.3 M undefined80.3 M undefined
2007446.2 M undefined95.5 M undefined71.9 M undefined

Guizhou Bailing Group Pharmaceutical Co stock margins

The Guizhou Bailing Group Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Guizhou Bailing Group Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Guizhou Bailing Group Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Guizhou Bailing Group Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Guizhou Bailing Group Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Guizhou Bailing Group Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Guizhou Bailing Group Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Guizhou Bailing Group Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Guizhou Bailing Group Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Guizhou Bailing Group Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Guizhou Bailing Group Pharmaceutical Co Margin History

Guizhou Bailing Group Pharmaceutical Co Gross marginGuizhou Bailing Group Pharmaceutical Co Profit marginGuizhou Bailing Group Pharmaceutical Co EBIT marginGuizhou Bailing Group Pharmaceutical Co Profit margin
202354.19 %-9.29 %-9.72 %
202259.39 %6.12 %3.9 %
202159.13 %7.37 %3.81 %
202056.13 %7.28 %4.94 %
201959.83 %16.05 %9.92 %
201859.75 %21.12 %17.95 %
201763.2 %24.15 %20.3 %
201664.11 %26.35 %21.78 %
201560.68 %25.94 %21.66 %
201460.79 %25.26 %19.72 %
201360.1 %25.35 %19.18 %
201253.6 %20.5 %16.22 %
201154.32 %24.53 %18.31 %
201051.47 %23.03 %18.31 %
200944.85 %19.55 %15.21 %
200845.72 %18.82 %13.22 %
200747.65 %21.4 %16.11 %

Guizhou Bailing Group Pharmaceutical Co Aktienanalyse

What does Guizhou Bailing Group Pharmaceutical Co do?

Guizhou Bailing Group Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Guizhou Bailing Group Pharmaceutical Co's Sales Figures

The sales figures of Guizhou Bailing Group Pharmaceutical Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Guizhou Bailing Group Pharmaceutical Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Guizhou Bailing Group Pharmaceutical Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Guizhou Bailing Group Pharmaceutical Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Guizhou Bailing Group Pharmaceutical Co stock

How much revenue did Guizhou Bailing Group Pharmaceutical Co generate this year?

Guizhou Bailing Group Pharmaceutical Co has achieved a revenue of 4.26 B CNY this year.

How much was the turnover of the company Guizhou Bailing Group Pharmaceutical Co compared to the previous year?

The revenue of Guizhou Bailing Group Pharmaceutical Co has increased by 20.42% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Guizhou Bailing Group Pharmaceutical Co?

The revenue of Guizhou Bailing Group Pharmaceutical Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Guizhou Bailing Group Pharmaceutical Co measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Guizhou Bailing Group Pharmaceutical Co so important for investors?

The revenue of Guizhou Bailing Group Pharmaceutical Co is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Guizhou Bailing Group Pharmaceutical Co pay?

Over the past 12 months, Guizhou Bailing Group Pharmaceutical Co paid a dividend of 0.22 CNY . This corresponds to a dividend yield of about 6.59 %. For the coming 12 months, Guizhou Bailing Group Pharmaceutical Co is expected to pay a dividend of 0 CNY.

What is the dividend yield of Guizhou Bailing Group Pharmaceutical Co?

The current dividend yield of Guizhou Bailing Group Pharmaceutical Co is 6.59 %.

When does Guizhou Bailing Group Pharmaceutical Co pay dividends?

Guizhou Bailing Group Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of May, July, July, June.

How secure is the dividend of Guizhou Bailing Group Pharmaceutical Co?

Guizhou Bailing Group Pharmaceutical Co paid dividends every year for the past 0 years.

What is the dividend of Guizhou Bailing Group Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Guizhou Bailing Group Pharmaceutical Co located?

Guizhou Bailing Group Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Guizhou Bailing Group Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Guizhou Bailing Group Pharmaceutical Co from 5/29/2020 amounting to 0.22 CNY, you needed to have the stock in your portfolio before the ex-date on 5/29/2020.

When did Guizhou Bailing Group Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 5/29/2020.

What was the dividend of Guizhou Bailing Group Pharmaceutical Co in the year 2023?

In the year 2023, Guizhou Bailing Group Pharmaceutical Co distributed 0 CNY as dividends.

In which currency does Guizhou Bailing Group Pharmaceutical Co pay out the dividend?

The dividends of Guizhou Bailing Group Pharmaceutical Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Guizhou Bailing Group Pharmaceutical Co

Our stock analysis for Guizhou Bailing Group Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Guizhou Bailing Group Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.